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Cancer cachexia is associated with the progressive depletion of
skeletal muscle mass and adipose fat deposits. We have recently
isolated 2 catabolic factors produced by cachexia-inducing
tumours that have the potential for inducing these changes in
body composition: (i) a proteolysis-inducing factor (PIF), which acts
on skeletal muscle to induce protein degradation and to inhibit
protein synthesis (Lorite et al, 1997). (ii) a lipid-mobilizing
factor (LMF), which acts directly to stimulate triglyceride
hydrolysis in adipocytes by stimulation of adenylate cyclase in a
GTP-dependent process (Hirai et al, 1998). Administration of
purified PIF to mice produces weight loss with depletion of
skeletal muscle without an effect on adipose tissue (Todorov
et al, 1996), while LMF produces a specific reduction in carcass
lipid with a tendency to increase the non-fat carcass mass (Hirai
et al, 1998). Induction of lipolysis in epididymal adipocytes is
attenuated by the b-adrenergic receptor (b-AR) antagonist
propranolol (Khan and Tisdale, 1999), suggesting that the action
of LMF may be mediated through a b-AR. b-Agonists stimulate
skeletal muscle hypertrophy in animals (Mersmann, 1998) and
some have been reported to increase protein synthesis in multin-
ucleated muscle cells in culture (Anderson et al, 1990; Grant
et al, 1990; McMillan et al, 1992). The mechanism requires an
increase in cyclic AMP, although the pathways leading from
cyclic AMP to changes in protein synthesis are incompletely
understood. However, phosphorylation of 40S ribosomal protein
S6 is elicited in a wide variety of cells and correlates with
increased rates of translation (Stefanovic et al, 1986). 
This study examines the effect of LMF on protein synthesis and
degradation in C2C12 murine myoblasts and in soleus muscle of mice,
and attempts to elucidate the role of cyclic AMP in this process. 
MATERIALS AND METHODS 
Chemicals and radiochemicals 
L-[2, 6-3H] Phenylalanine (sp. act. 2.07 TBq mmol–1), 2-deoxy-D
[2, 6-3H] glucose (sp. act. 1.63 TBq mmol–1) and 8[3H] cyclic
AMP (sp. act. 888 GBq mmol–1) were purchased from Amersham
Lifesciences, Bucks, UK. 5-Methyl [3H] thymidine (sp. act. 3.1
TBq mmol–1) was purchased from NEN Research Products, Herts,
UK. MDL12330A, H8, rapamycin, PD 98059, wortmannin, LY
294002 and forskolin were purchased from Calbiochem,
Nottingham, UK, while cyclic AMP-dependent protein kinase was
purchased from Sigma Chemical Co, Dorset, UK. SR 59230A was
a gift from Dr L Manara, Sanofi Winthrop, Italy. Fetal calf serum
(FCS) and Dulbecco’s modified Eagle’s medium (DMEM) were
purchased from Life Technologies, Paisley, Scotland. 
Cell culture 
C2C12 murine myoblasts were cultured in DMEM supplemented
with 12% FCS, 1% penicillin-streptomycin, in a humidified
atmosphere of 5% CO2 in air at 37˚C. MAC16 cells were main-
tained in RPMI 1640 medium containing 5% FCS. All experi-
ments were performed with the cells in a sub-confluent state. 
Purification of LMF 
LMF was purified from the urine of cachectic patients with
pancreatic carcinoma using a combination of batch extraction on
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DEAE-cellulose and hydrophobic interaction chromatography
(Todorov et al, 1996 ) Particulate material was removed from
urine by centrifugation at 3000 g for 10 min followed by dilution
with 4 vol 10 mM Tris. HCl, pH 8.0. DEAE cellulose (10 g l–1 of
original urine) was added and the mixture was stirred for 2 h at
4˚C. The DEAE-cellulose was recovered by low speed centrifu-
gation and LMF bioactivity, determined by glycerol release from
epididymal adipocytes (Khan and Tisdale, 1999), was eluted
with 0.5 M NaCl in 10 mM Tris. HCl, pH 8.0. The eluate was
equilibrated against PBS and concentrated to 1 ml before further
purification using a Resource-Iso HPLC column (Pharmacia
Biotech, St Albans, Herts, UK) employing a decreasing
(NH4)2SO4 concentration from 1.5 M. Active fractions
containing LMF eluted at 0.6 M (NH4)2SO4, and were desalted
before use by washing 5 times against PBS using an Amicon
filtration cell. LMF eluted as a single protein band of Mr 43000
as determined by Coomassie blue staining of a 12% SDS poly-
acrylamide gel (Figure 1). 
Precursor incorporation 
C2C12 myoblasts were seeded at 5 ´ 104 cells ml–1 and MAC16 at
105 cells ml–1 in 6-well multidishes containing 2 ml medium per
well. After 24 h various concentrations of LMF was added and left
for a further 24 h period. During the last 60 min of incubation the
cells were incubated with 1.5 mmol L-phenylalanine containing
37 kBq of L-[2, 6-3H] phenylalanine. The reaction was terminated
by removal of medium and washing the cells 3 times with ice-cold
PBS. The cells were then incubated at 40˚C for 20 min with 1 ml
ice-cold 0.2 M perchloric acid, which was replaced with 1 ml
0.3 M NaOH and incubation continued at 4˚C for a further 30 min,
followed by a further 20 min at 37˚C. Cellular protein was precipi-
tated with 2 M perchloric acid (0.5 ml) for 20 min at 4˚C, followed
by centrifugation at 3000 g for 10 min at 4˚C. The pellet, which
comprised DNA and protein was dissolved in 1 ml of 0.3 M NaOH,
and an aliquot (20 ml) was used to measure protein concentration
using the Bio-Rad reagent (Sigma Chemical Co, Dorset, UK). 
The radioactivity in 0.5 ml was determined using a 2000CA Tri-
Carb liquid scintillation analyser. The rate of protein synthesis was
calculated as dpm mg protein–1 h–1 as described (Southorn and
Palmer, 1990). The protocol for DNA synthesis was the same as
above except that methyl [3H] thymidine (0.5 mCi) was added at the
same time as LMF and left for 48 h. Protein was precipitated using
ice-cold 5% trichloroacetic acid for 1 h at 4˚C. Incorporation of 2-
deoxy-D [2, 6-3H] glucose ([3H] 2DG) was determined in C2C12
myoblasts 24 h after addition of LMF. The media was removed, and
the cells were rinsed once with Krebs Ringer bicarbonate buffer,
followed by incubation for 30 min at 37˚C in a further 1 ml of Krebs
Ringer bicarbonate, together with 0.1 mM [3H] 2DG (sp. act 74
MBq mmol–1). Cells were washed 3 times with ice-cold PBS and
incubated on ice for 1 h with lM NaOH (1 ml) and the amount of
radioactivity incorporated was determined. 
Cyclic AMP determination 
C2C12 myoblasts were seeded at 4 ´ 104 cells ml–1 in 1 ml medium
in a 24-well multi-dish and left for 48 h before addition of LMF
for 30 min at 37˚C. The medium was removed and replaced with
0.5 ml 20 mM HEPES, pH 7.5, 5 mM EDTA and 0.1 mM
isobutylmethylxanthine and then the cells were heated on a boiling
water bath for 5 min, followed by cooling on ice for 10 min. The
cell extracts were sonicated on ice followed by centrifugation at
5000 rpm for 15 min. To 50 ml of the cell extract was added 
925 Bq of [8-3H] cyclic AMP and 20 mg of cyclic AMP-dependent
protein kinase and incubated for 2 h at 4˚C. Unbound cyclic AMP
was removed by adsorption onto charcoal and the concentration of
cyclic AMP in the sample determined by comparison with stan-
dard curves using known concentrations of cyclic AMP. 
Determination of the activation of protein kinase A (PKA) 
C2C12 myoblasts were treated with LMF for 24 h and cytosolic
fractions were produced by sonication in 0.25 M sucrose, 
1 mM EDTA, 1 mM dithiothreitol, 10 mg ml–1 leupeptin and 10 mg
ml–1 antipain followed by high speed centrifugation. The activa-
tion of PKA in the cellular supernatants was determined using the
Pierce colourimetric PKA assay kit, Spinzyme™ Format
(Rockford, IL, USA) using peptide substrate (Kemptide) labelled
with fluorescent dye. The phosphorylated product was quantitated
by measuring absorbance at 570 nm. 
Measurement of proteasome activity 
C2C12 myoblasts were treated with different concentrations of
LMF for 24 h and the activity of the 26S proteasome was deter-
mined according to the method of Orino et al (1991). Cellular
supernatants were prepared in 20 mM Tris. HCl, pH 7.5, 2 mM
ATP, 5 mM MgCl2 and 1 mM dithiothreitol and incubated with the
fluorescent substrate succinyl-LLVY-MCA (0.1 mM) in 100 mM
Tris. HCl, pH 8.0. The reaction was terminated by the addition of
80 mM sodium acetate and the fluorescence was measured with an
excitation of 360 nm and an emission of 460 nm. The protein
concentration of the sample was determined using the Bradford
assay (Sigma Chemical Co, Dorset, UK). 
Western blot analysis 
Samples (5 mg protein) were resolved on 10% sodium dodecylsul-
fate, polyacrylamide gels and transferred to 0.45 mm nitrocellulose
membranes (Hybond A, Amersham, UK), which had been blocked
12
Figure 1 Electrophoretic separation of proteins on a 12% SDS
polyacrylamide gel. Lane 1 molecular weight markers; Lane 2 LMF 
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with 5% Marvel in Tris buffered saline (TBS) at 4˚C overnight.
The primary antibodies used were mouse MCP231, a mouse
monoclonal antibody to 20S proteasome subunits a1, 2, 3, 5, 6 and
7 (Affiniti Research Products, Exeter, UK), and mouse mono-
clonal antibody to myosin (Novacastra, Newcastle-upon-Tyne,
UK), at a dilution of 1:1000 and 1:200 respectively. The secondary
antibody was peroxidase-conjugated rabbit anti-mouse (Dako Ltd,
Cambridge, UK) used at a 1:2000 dilution. Incubation was carried
out for 1 h at room temperature, and development was by
enhanced chemiluminescence (ECL) (Amersham, UK). 
Determination of protein synthesis and protein
degradation in soleus muscle after LMF administration 
Ex-breeder male NMRI mice (average weight 44.50 g) were
administered LMF (8 mg, b.d. iv) for 48 h. After termination
soleus muscles were isolated and both protein synthesis and degra-
dation were determined essentially as described (Smith and
Tisdale, 1993). Protein synthesis was determined by the incorpora-
tion of L-[4-3H] phenylalanine into protein during a 2 h incuba-
tion, and the rate of protein synthesis was calculated by dividing
the amount of protein bound radioactivity by the amount of acid
soluble radioactivity. Protein catabolism was determined by the
tyrosine release assay as described (Lorite et al, 1997). Tyrosine
release from soleus muscles was determined during a 2 h incuba-
tion in Krebs–Henseleit buffer containing 6 mM D-glucose,
1.2 mg ml–1 bovine serum albumin and 130 mg ml–1 cyclohex-
imide. Tyrosine was quantitated by a fluorometric method
(Waalkes and Undenfriend, 1957) at 570 nm on a Perkin–Elmer
LS-5 luminescence spectrometer. The animal ethics meet the
standards required by the UKCCCR Guidelines. 
Assay of cathepsins L and B 
C2C12 myoblasts pre-incubated for 24 h with LMF were homoge-
nized in 250 mM sucrose, 2 mM EGTA, 2 mM EDTA, 20 mM
Tris. HCl, pH 7.4, containing 0.2% Triton X-100 followed by
sonication. The supernatants formed after centrifugation at 
18 000 g for 15 min were used to determine cathepsin activity as
described (Lorite et al, 1998) using the fluorometric substrates
N-CBZ-Phe-Arg-7-amids-4-methylcoumarin for cathepsin L
and N-CBZ-Arg-Arg-7-amido-4-methylcoumarin for cathepsin
B. The flourescence of the free aminomethylcoumarin was deter-
mined at an excitation wavelength of 370 nm and an emission
wavelength of 430 nm. 
RESULTS 
A dose–response curve showing the effect of increasing concen-
trations of LMF on protein synthesis in C2C12 myoblasts is shown
in Figure 2A. Protein synthesis was increased in a concentration-
dependent manner, with a maximal 40% stimulation above
control values at a concentration of LMF of 580 nM (P < 0.001
from control). A similar dose–response relationship was obtained
for LMF on protein synthesis in C2C12 myotubes (Figure 2B), and
in MAC16 cells (Figure 2C). LMF also produced a stimulation of
2-deoxyglucose uptake into C2C12 myoblasts (Figure 2D) and
MAC16 tumour cells (Figure 2E) with a dose–response curve
similar to that for stimulation of protein synthesis. There was no
effect of LMF on cell number or [3H] thymidine incorporation
into any cell line, showing the action of LMF to be specific for
protein synthesis. LMF produced an early (within 30 min)
increase in cyclic AMP levels in C2C12 myoblasts, which was
linearly (r2 = 0.973, P = 0.004) related to the increase in protein
synthesis after 24 h (Figure 3). This suggests that the 2 effects
may be related. There was an increase in protein kinase A (PKA)
with increasing concentrations of LMF, which reached maximum
stimulation at 58 nM LMF and was independent of LMF concen-
tration up to 580 nM (P < 0.05 from control) (Figure 4). The
stimulating effect of LMF on protein synthesis in C2C12
myoblasts was attenuated by the adenylate cyclase inhibitor
MDL12330A, but not by the cyclic AMP-dependent protein kinase
inhibitor H8 at 10 mM (Table 1). Both forskolin (25 mM) and
dibutryl cyclic AMP (1 mM) stimulated protein synthesis,
confirming a role for cyclic AMP in the process. Stimulation of
protein synthesis by forskolin, but not by dibutryl cyclic AMP
was additive with that of LMF (Table 1). The induction of
protein synthesis in C2C12 myoblasts by LMF was partially inhib-
ited by a polyclonal antibody to zinc-a2-glycoprotein (ZAG)
(Table 2), and the non-specific b-adrenergic receptor antagonist,
propranolol (10 mM) (Figure 5). The specific b3-adrenergic
receptor antagonist, SR59230A (Nisoli et al, 1996) at a concen-
tration of 10–5 M significantly reduced LMF stimulation of
protein synthesis down to control levels (Figure 6). This suggests
that stimulation of protein synthesis by LMF may be mediated
through a b3-adrenergic receptor. There was no effect on the
LMF stimulation of protein synthesis by inhibitors of p70S6
kinase (rapamycin, 0.5 ng ml–1), mitogen-activated protein
kinase (PD 98059, 0.63 mM), or of phosphatidylinositide-3-OH
kinase (wortmannin, 0.02 mM, or LY 294002, 0.05 mM) 
(Table 2). 
Administration of LMF (8 mg, i.v., b.d.) to ex-breeder male NMRI
mice caused a progressive decrease in body weight (Figure 7), which
became significantly different from control animals administered
PBS within 24 h of the first injection. Despite this overall loss of
body weight, which was exclusively fat, soleus muscles from LMF
treated animals showed a 69% increase in protein synthesis (P =
0.006 from control) (Figure 8A) and a 26% decrease in protein degra-
dation (P = 0.03 from control) (Figure 8B) 48 h after the first injec-
tion of LMF. Myosin levels were also increased in soleus muscle
from mice receiving LMF (Figure 8C). Densitometric analysis
showed a 46 ± 9% (P < 0.05 from control) increase in myosin levels
after LMF. In C2C12 myoblasts LMF had no effect on the activity of
the lysosomal enzymes, cathepsins L or B (data not shown), but
produced a progressive decrease in the functional activity of the
proteasome, as determined by the ‘chymotrypsin-like’ enzyme
activity, using the fluorogenic substrate succinyl LLVY-MCA
(Figure 9A). Western blotting of cellular supernatants of LMF treated
cells with MCP231 antibody, a murine monoclonal to the 20S protea-
some, which reacts with the a-type subunits, showed a decrease in
expression with increase in LMF concentration (Figure 9B) paral-
lelling the decrease in functional activity. Unlike LMF, PIF produced
an increase in expression of the 20S proteasome a-subunits, which
varied with the concentration, reaching a maximal 77% increase at
10.4 nm PIF (Figure 10A). Addition of LMF (580 nM) completely
attenuated the increased expression of the 20S a-subunits in the pres-
ence of PIF (Figure 10B). 
DISCUSSION 
Loss of skeletal muscle protein is a characteristic feature of cancer
cachexia leading to immobility of the patient and eventually toEffect of LMF on protein synthesis 1651
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death (Tisdale, 1997). This process has been attributed to tumour
production of PIF, which inhibits protein synthesis and increases
protein catabolism in skeletal muscle (Todorov et al, 1996; Lorite
et al, 1997). However, the present study shows that LMF, also
produced by cachexia-inducing tumours, appears to oppose the
action of PIF by increasing protein synthesis and decreasing
protein degradation in muscle. This action of LMF has been
demonstrated in the soleus muscles of mice administered LMF as
well as in isolated myoblasts and myotubes. The effect of LMF on
protein synthesis was attenuated, both by propranolol, a non-
specific  b-adrenergic agonist as well as by SR59230A, which has
been reported (Nisoli et al, 1996) to have a 10-fold selectivity for
the b3-over the b1-AR, suggesting that the action of LMF may be
mediated through a b-AR. b-Adrenergic agonists have been shown
to lead to increased muscle protein synthesis, accompanied or
followed by decreased protein degradation (Bell et al, 1998),
through a cyclic AMP-dependent pathway. The increase in protein
synthesis produced by LMF in C2C12 myoblasts was also linearly
related to increase in cyclic AMP levels and attenuated by the
adenylate cyclase inhibitor, MDL12330A. The mechanisms leading
from an increase in cyclic AMP to increased protein synthesis
have not been fully elucidated. 
Gene regulation by polypeptide growth factors is thought to be
mediated by transcription factors controlled either by the mitogen-
activated protein (MAP) kinase pathway (Davis, 1993) or the
p70S6 kinase (p70s6k) (Sturgill and Wu, 1991), which rapidly
phosphorylates the S6 protein of the 40S ribosomal subunit.
Stimulation of protein synthesis in L6 myoblasts was blocked by
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Figure 2 Dose–response curves showing the effect of LMF on protein synthesis in C2C12 myoblasts (A), C2C12 myotubes (B) and MAC16 cells (C) and 
2-deoxyglucose uptake in C2C12 myoblasts (D) and MAC16 cells (E) after 24 h incubation with LMF. Values are represented as mean ± SEM where n = 3 and
the experiment was repeated 4 times. Differences from controls incubated in the absence of LMF were determined by one-way ANOVA with
Student–Newman–Keuls test and are indicated as a, P < 0.05, b, P < 0.01 and c, P < 0.001 
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inhibitors of p70s6k (rapamycin) and MAP kinase (PD-98059), as well
as by inhibitors of phosphatidylinositide-3-OH kinase (wortmannin)
(Kimball et al, 1998). However, neither rapamycin, PD-98059, wort-
mannin or the potent and specific phosphatidylinositide-3-OH
kinase had any effect on LMF stimulation of protein synthesis in
C2C12 murine myoblasts, suggesting an alternative pathway was
involved. While in COS-7 cells cyclic AMP activates the MAP
kinase pathway (Faure et al, 1994) in rat phaeochromocytoma,
PC12, it stimulates the MAP kinase isoenzyme extracellular
signal-regulated kinase 1 (ERK1) (Frodin et al, 1994). In addition
the ribosomal protein S6 is directly phosphorylated by cyclic
AMP-dependent protein kinase (Wettenhall and Cohen, 1992).
Transcriptional regulation following stimulation of adenylate
cyclase can also be mediated by the family of cyclic AMP-
response element (CRE)-binding proteins (Habener, 1990). These
factors are phosphorylated by PKA with increasing concentrations
of cyclic AMP, leading to high stimulation in the transactivating
potential (de Groot et al, 1993). These CRE-binding proteins may
be involved in LMF stimulation of protein synthesis, although the
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lack of inhibition of PKA by H8 at 10 mM would negate against
the possibility. However, it is possible that higher concentrations
of H8 are required for inhibition of PKA in this system. This
requires further investigation. 
Despite the stimulatory effect of LMF on protein synthesis there
was no effect on DNA synthesis or cell number, suggesting a
hypertrophic response to this tumour factor. Nevertheless protein
synthesis was also enhanced in tumour cells suggesting that LMF
is potentially a growth factor for the tumour. LMF also stimulated
2-deoxyglucose uptake into C2C12 myoblasts which suggests that it
facilitates glucose utilization. Administration of LMF to mice
produces a decrease in blood glucose (Hirai et al, 1998)
confirming the ability to stimulate glucose utilization. Li and
Adrian (1999) have also reported that pancreatic cancer cells
produce a bioactive factor which stimulates glucose uptake and
utilization in murine myoblasts. Although the reported Mr of this
factor is much lower than that of LMF, in separate experiments
(unpublished) we have shown LMF to undergo tryptic cleavage to
yield a bioactive fragment of comparable molecular weight. 
In addition to stimulation of protein synthesis LMF also attenu-
ates protein catabolism in skeletal muscle. The ubiquitin–
proteasome system is considered to be the major pathway for
selective protein breakdown in muscle, while lysosomal proteolysis
plays only a minor role (Attaix and Taillander, 1998). While there is
no effect of LMF on the lysosomal proteolytic enzymes cathepsins
B and L, there is a significant inhibition of proteasome catalytic
activity, through a decreased expression of the proteasome a-type
subunits. Since protein catabolism in cachexia appears to be due to
an up-regulation of proteasome expression (Lorite et al, 1998) then
LMF appears to be antagonistic to tumour proteolytic factors, such
as PIF, and as such may modulate the rate of loss of skeletal
muscle mass. In the MAC16 murine cachexia model LMF bioac-
tivity is maximally elevated at 15% weight loss and thereafter
declines (Groundwater et al, 1990). In this model a decrease in
protein synthesis and an increase in protein degradation is not seen
until the weight loss exceeds 16% (Smith and Tisdale, 1993). This
suggests that either PIF production is not apparent at low weight
loss or that LMF attenuates the action of PIF. This can be deter-
mined by administration of the pure factors to mice. 
Thus LMF increases muscle mass by an increase in protein
synthesis and a decrease in protein catabolism. The effect on
protein synthesis appears to arise from increases in intracellular
cyclic AMP, possibly mediated through stimulation of a b3-
adrenergic receptor. Since LMF was also found to stimulate
Table 2 The effect of potential inhibitors on LMF-induced protein synthesis in C2C12 myoblastsa
P valueb
Treatment % Control protein synthesis 
From control From LMF  (± SEM)
LMF (406 nM) 132 ± 8 <0.01 – 
LY294002 (50 nM) 89 ± 3 NS – 
LY294002 (50 nM) + LMF 128 ± 10 – NS 
Wortmannin (20 nM) 77 ± 10 < 0.05 – 
Wortmannin (20 nM) + LMF 107 ± 6 – NSc
Rapamycin (0.5 ng ml–1) 62 ± 7 <0.001 – 
Rapamycin (0.5 ng ml–1) + LMF 93 ± 2 – NSc
PD98059 (625 nM) 92 ± 5 NS – 
PD98059 (625 nM) + LMF 129 ± 4 – NS 
Anti-ZAG (10 mg ml–1) 100 ± 5 NS – 
LMF (406 nM) + Anti-ZAG 120 ± 7 – <0.05
LMF (580 nM) 142 ± 6 <0.01 – 
LMF (580 nM) + Anti-ZAG 120 ± 6 – <0.05 
aAgents were added 1 h prior to LMF and protein synthesis determined after 24 h. bStatistical analysis performed
using one-way ANOVA with Student–Newman–Keuls test. cBased on new reduced control value. 
Table 1 The effect of agents influencing intracellular cyclic AMP on LMF-induced protein synthesis in C2C12
myoblastsa
P valueb
Treatment % Control protein synthesis 
From control From LMF  (± SEM)
LMF (580 nM) 136 ± 7 <0.001 – 
MDL12330A (20 mM) 96 ± 10 NS – 
MDL12330A (20 mM) + LMF 113 ± 14 – < 0.05 
H8 (10 mM) 104 ± 3 NS – 
H8 (10 mM) + LMF 125 ± 2 – NS 
Forskolin (25 mM) 158 ± 7 <0.001 – 
Forskolin (25 mM) + LMF 178 ± 5 – < 0.001 
Dibutyryl cyclic AMP (1 mM) 125 ± 4 <0.01 – 
Dibutyryl cyclic AMP (1 mM) + LMF 148 ± 3 – NS 
aAgents were added 1 h prior to LMF and protein synthesis determined after 24 h. bStatistical analysis performed
using one-way ANOVA with Student–Newman–Keuls test. 1654 BS Islam-Ali and MJ Tisdale 
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Figure 8 Effect of LMF on protein synthesis (A) and protein degradation 
(B) in soleus muscle of exbreeder male NMRI mice in comparison with
animals receiving PBS. Values are shown as means ± SEM where n = 6.
Differences from control values were determined by Student’s t-test and are
indicated as a, P = 0.03 and b, P = 0.006. (C) Western blot analysis of
soluble extracts of gastrocnemius muscle of mice administered PBS (lanes
1–5) or LMF (lanes 6–10) detected with a mouse monoclonal antibody to
myosin. Blots were developed by ECL 
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Figure 9 (A) Chymotryptic activity of soluble extracts of C2C12 myoblasts 24 h
after treatment with LMF determined using the fluorogenic substrate suc
LLVY-MCA. Results are shown as mean ± SEM where n = 3 and the
experiment was repeated 4 times. Differences from controls in the absence
of LMF are indicated as a, P < 0.05. (B) Western blot analysis of soluble
extracts of C2C12 myoblasts from cells treated with PBS (lane 1) or 11.6 nM
(lane 2); 58 nM (lane 3); 174 nM (lane 4); 406 nM (lane 5) or 580 nM (lane 6)
LMF for 24 h and detected with a mouse monoclonal antibody to the 20S
proteasome a-subunits. The blot was developed by ECL. Densitometric
analysis showed LMF (nM) to produce the following percentage of the control
(lane 1), 11.6 nM (89%); 58 nM (76%); 174 nM (52%); 406 nM (47%); 
580 nM (35%). A parallel gel was silver-stained to ensure equal loading 
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Figure 10 (A) Western blot analysis and densitometric scans of soluble extracts of C2C12 myoblasts treated with PBS (lane 1) or 1 nM (lane 2); 2 nM (lane 3);
5 nM (lane 4); 8.3 nM (lane 5); 10 nM (lane 6) PIF for 24 h and detected with a mouse monoclonal antibody to the 20S proteasome a-subunits. (B) Western blot
analysis of C2C12 myoblasts treated with increasing concentrations of PIF for 24 h in the presence of LMF (580 nM). The lanes (7–12) represent the same
concentrations of PIF as depicted in (A) Effect of LMF on protein synthesis 1655
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protein synthesis in tumour cells it may function to increase
overall tumour bulk without affecting cellular proliferation. 
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